P21
Neurogenic research peptide (Cerebrolysin/CNTF-related)
A synthetic peptide studied in neurogenesis research.
Also referenced as: P021
Overview
P21 (also referred to as P021 in the literature) is a small peptidergic compound derived from a biologically active region of ciliary neurotrophic factor (CNTF), developed in academic neuroscience research as a neurogenic candidate.
At a glance
What P21 does
P21 (also written P021) is a small modified tetrapeptide, Ac-DGGL-amide, engineered from the active region of ciliary neurotrophic factor (CNTF). The design goal was to capture CNTF's neurotrophic activity in a molecule small and lipophilic enough to cross the blood-brain barrier while avoiding CNTF's systemic side effects. What it does in research is enhance adult hippocampal neurogenesis and, in Alzheimer's disease models, simultaneously reduce tau pathology and rescue memory.
Its mechanism is unusual for a CNTF mimetic: rather than fully activating CNTF's receptor complex, P21 is reported to act partly by inhibiting leukemia inhibitory factor (LIF) signaling and by increasing BDNF expression, which together boost dentate gyrus neurogenesis and dendritic/synaptic integrity. Downstream, it has been shown to prevent dendritic spine loss, reduce hyperphosphorylation of tau at multiple epitopes (thereby limiting neurofibrillary tangle formation), and preserve synaptic markers in transgenic mouse brains.
All of this evidence should be read with real caution. In transgenic Alzheimer's mouse models, chronic preventive P021 treatment has been reported to completely prevent cognitive impairment in the Morris water maze while sustaining elevated neurogenesis, but essentially the entire body of work originates from a single research group (Iqbal and colleagues), and there are no human clinical trials. It is therefore a promising but unreplicated, preclinical-only compound.
Effects reported in research
- Increased adult hippocampal (dentate gyrus) neurogenesis in rodents (animal).
- Prevented cognitive impairment in the Morris water maze in transgenic Alzheimer's mouse models under chronic preventive dosing (animal).
- Reduced tau hyperphosphorylation at multiple epitopes, limiting neurofibrillary tangle formation (animal).
- Increased BDNF expression in the brain (preclinical).
- Reported to act partly by inhibiting leukemia inhibitory factor (LIF) signaling (preclinical, proposed mechanism).
- Prevented dendritic spine loss and preserved synaptic markers in disease-model mice (animal).
- Designed for blood-brain-barrier penetration as a small CNTF-derived tetrapeptide (preclinical characterization).
- Evidence limited to a single research group with no human trials to date.
Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.
Mechanism of action
P021 is described as an adamantylated, blood-brain-barrier-permeable derivative of a CNTF peptide fragment. Preclinical research reports it can enhance neurogenesis and neurotrophic signaling, including effects on BDNF, and has been studied for reduction of abnormal tau hyperphosphorylation in models of neurodegeneration. Its detailed human pharmacology is not established.
Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
What it's studied for
Research contexts in which P21 appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.
Key characteristics
- Derived from a peptide region of ciliary neurotrophic factor (CNTF)
- Adamantylation is reported to improve stability and brain penetration
- Studied preclinically for neurogenesis and effects on tau pathology
- Investigated as a neurogenic/neuroprotective candidate, primarily in rodent models
- Research-only; no approved human clinical use
Reported research dosing reference only
Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. P21 is a research compound.
Vendor and community materials cite subcutaneous and intranasal microgram-to-milligram ranges, but no dose is anchored to a completed human trial, so figures should be treated as unvalidated. These are reference figures for research context only, not human dosing guidance.
No published human PK/half-life or validated human dose; commonly cited ranges are community-derived, not trial-anchored
How it compares
P21/P021 is distinguished by its CNTF-derived, neurogenesis-focused mechanism, differing from HGF-modulating (Dihexa) or melanocortin (Semax) peptides.
Commonly studied alongside
Compounds frequently researched together with P21 in the literature. Cross-referenced for research context — not a usage or combination recommendation.
Compare and calculate
Side-by-side pages for the pairings the literature already documents for P21, plus the unit-conversion reference for a reconstituted vial. Factual comparisons of documented characteristics — not a recommendation to combine or use any compound.
Handling & Stability
Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.
- Avoid repeated freeze-thaw cycles
- Verify supplier lot and Certificate of Analysis
- Follow institutional lab-safety protocols
Analytical & COA Concepts
Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:
Category Context
P21 sits in the Cognitive & Nootropic area of the PeptiDex library.
- Entry type: Research compound reference
- Cognitive & Nootropic category hub →
- Browse the full library →
- Glossary of terms →
Where researchers source P21
For researchers studying P21, third-party suppliers such as Practically Natty Peptides offer research-grade material, third-party tests every batch and provides Certificates of Analysis on request, and ship from the US.
PeptiDex does not maintain a direct supplier listing for this compound. The link above goes to a third-party research-supplier directory.
Frequently asked questions
What is P21 (P021)?
P21, also written P021, is a synthetic peptidomimetic derived from an active region of ciliary neurotrophic factor (CNTF), with an adamantylated glycine added to improve stability and lipophilicity. It is studied in preclinical models of neurogenesis, synaptic plasticity, and neurodegeneration.
What is P21's proposed mechanism?
In preclinical reports P21 is proposed to enhance BDNF expression and downstream TrkB/CREB signaling while avoiding the leukemia-inhibitory-factor-associated side effects of the parent molecule CNTF. This is put forward as the basis for its reported neurogenic and neurotrophic effects.
Why was P21 derived from CNTF rather than using CNTF itself?
Native CNTF has poor drug-like properties and dose-limiting adverse effects, which restricted its therapeutic development. P21 was engineered as a small, more stable mimetic of an active CNTF region to retain neurotrophic signaling while improving stability and tolerability in preclinical models.
What is the evidence base for P21?
The evidence for P21 is preclinical, primarily rodent studies, some running up to about 12 months and reporting sustained neurogenic and neuroprotective effects. There are no completed human clinical trials, so human dosing and safety are not established.
How does P21 relate to Adamax?
P21 and Adamax are sometimes conflated in vendor materials, but they are distinct compounds: P21 is a CNTF-derived neurotrophic mimetic, while Adamax is an adamantane-modified analog in the Semax/ACTH family. Both are studied around BDNF-linked mechanisms, which contributes to the confusion.
Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.
References
Primary literature indexed in PubMed for P21. Listing a study records that it exists and is indexed — it is not a claim of efficacy, a therapeutic indication, or an endorsement of its conclusions. Much of this literature is preclinical (in-vitro or animal-model).
- Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease
- Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome
- Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease
Each reference was checked against its PubMed record on 2026-07-28: the PMID resolves and the title, journal and year match. Where no indexed literature exists for a compound, PeptiDex says so rather than substituting a citation about a different molecule. See the editorial policy.